Faeth Therapeutics (FTH) Total Debt (2020 - 2021)
Faeth Therapeutics' (FTH) quarterly Total Debt came in at $567000.0 in Q2 2021, little changed quarter-over-quarter from $567000.0 in Q1 2021.
Powered by 
Analysis
Faeth Therapeutics (FTH) Total Debt (2020 - 2021) Analysis & Trends
Faeth Therapeutics (FTH) has reported Total Debt for 2 consecutive years, with $567000.0 the latest figure, recorded in Q2 2021.
- For the quarter ending Q2 2021, Total Debt changed N/A year-over-year to $567000.0; the trailing twelve-month figure through Jun 2021 stood at $567000.0 (changed N/A YoY), and the FY2020 full-year result was $567000.0, changed N/A from the prior year.
- Total Debt steadied at $567000.0 in Q2 2021 per FTH's latest filing, from $567000.0 in the prior quarter.
- Across five years, Total Debt topped out at $567000.0 in Q4 2020 and bottomed at $567000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Faeth Therapeutics | 218.99 Mn | 218.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 567,000.00 |
| Mar 31, 2021 | 567,000.00 |
| Dec 31, 2020 | 567,000.00 |